Cover Image

Not for Sale

View/Hide Left Panel
Click for next page ( 9

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 8
Colloquium Conservation of a portion of the S. cerevisiae Ure2p prion domain that interacts with the full-length protein Herman K. Edskes and Reed B. Wickner* Laboratory of Biochemistry and Genetics, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0830 The [URE3] prion of Saccharomyces cerevisiae is a self-propagating inactive amyloid form of the Ure2 protein. Ure2p residues 1-65 constitute the prion domain, and the remaining C-terminal portion regulates nitrogen catabolism. We have examined the URE2 genes of wild-type isolates of S. cerevisiae and those of several pathogenic yeasts and a filamentous fungus. We find that the normal function of the S. cerevisiae Ure2p in nitrogen regulation is fully complemented by the Ure2p of Candida albicans, Candida glabrata, Candida kefyr, Candida maltose, Saccharomyces bayanus, and Saccharomyces para- doxus, all of which have high homology in the C-terminal nitrogen regulation domain. However, there is considerable divergence of their N-terminal domains from that of Ure2p of S. cerevisiae. lURE3s'] showed efficient transmission into S. cerevisiae ure2A cells if express- ing a Ure2p of species within Saccharomyces. However, [URE3S'] did not seed self-propagating inactivation of the Ure2p's from the other yeasts. When overexpressed as a fusion with green fluorescent protein, residues 5-47 of the S. cerevisiae prion domain are necessary for curing the [URE3] prion. Residues 11-39 are necessary for an inactivating interaction with the full-length Ure2p. A nearly identical region is highly conserved among many of the yeasts examined in this study, despite the wide divergence of sequences found in other parts of the N-terminal domains. the word "prior" means "infectious protein." Considerable ~ evidence supports a prion basis for the transmissible spon- giform encephalopathies (TSEs) of mammals, with an amyloid form of the PrP protein as the culprit (1~. The gene for PrP controls the clinical and pathological features of the TSEs (2-7~. The scrapie agent is far more radiation resistant than even small genome viruses (8), and purification of the infectious agent purifies an amyloid form of PrP (9~. PrP is clearly necessary for and central to infectivity, but showing that it is sufficient has been difficult. LURES] (10) and tPSI+] (11) are nonchromosomal genes of S. cerevisiae whose molecular basis was long obscure. Genetic evi- dence first identified LURES] and tPSI+] as prions of the yeast Ure2p and Sup35p, respectively (12~. Three criteria distinguishing prions from viruses and plasmids are (i) after curing a prion, it can arise again de novo in the cured strain, (ii) overexpression of the protein increases the frequency with which the prion arises de nova, and (iii) the prior's propagation depends on the chromosomal gene encoding the protein, but the presence of the prion has a similar phenotype to recessive mutation of the chromosomal gene (12~. Both LURES] and tPSI+] satisfy all three criteria as prions of Ure2p and Sup35p, respectively (reviewed in refs. 13-16) Ure2p is a regulator of nitrogen catabolism, acting by binding to the Gln-3 GATA transcription factor and thereby keeping the latter in the cytoplasm when the medium contains a rich nitrogen source such as NH3 or glutamine (17-22~. This prevents the transcription of genes, such as DALS, encoding enzymes or transporters needed to use poor nitrogen sources (23-25~. The N-terminal 65-90 16384-16391 1 PNAS 1 December 10, 2002 1 vol 99 1 suppl. 4 residues of Ure2p largely determine the prion properties of the 354 residue protein (26, 27), whereas the C-terminal 261 residues are sufficient for nitrogen regulation (18, 26~. Overexpression of the prion domain is sufficient to induce the de novo appearance of LURES] at rates far higher than even the elevated rates observed on overexpression of the full-length Ure2p protein (26, 27~. A similar phenomenon has been observed for the Sup35p prion domain and induction of tPSI+] appearance (28~. Moreover, expression of just the prion domain is sufficient to maintain LURES] (29~. The first biochemical evidence for the yeast prions and hint of their molecular basis was the observation that Ure2p is protease- resistant in extracts of LURES] cells, but not in extracts of normal strains (26~. The similarity of this finding to the protease resistance of PrP in scrapie brains (9) was, of course, highly suggestive. Moreover, it is the prion domain of Ure2p that forms the protease- resistant core of the prion form (26, 30, 314. Ure2p is aggregated in vivo specifically in LURED strains, and this aggregation requires the prion domain (32~. Ure2p purified from yeast is a stably soluble dimer (30, 33), but the synthetic prion domain, Ure2pl-65, spontaneously and rapidly forms amyloid fibers in vitro (30~. Moreover, in the same way that expression of the prion domain induces the de novo appearance of the LURES] prion in viva, its presence in vitro induces the full-length Ure2p to form amyloid filaments containing both the prion domain fragment and the full-length molecule (30~. The self-propagation of this reaction, the specificity for the Ure2p prion domain, and the similarity of the pro/ease-resistance patterns of this in vitro amyloid to that of Ure2p in LURES] cells strongly support the concept that LURES] is a self-propagating inactive amyloid form of Ure2p. Ure2p filaments have been directly observed in vivo specifically in tURE3] cells (31~. These filaments were observed in large networks, localized to limited areas of the cytoplasm, with generally only a single network observed in a single cell section. Other areas of the cytoplasm were depleted of Ure2p (31~. Several lines of evidence suggest a structure for the Ure2p amyloid in which the prion domain forms a central ,13-sheet-rich core surrounded by the appended functional domain. Protease digestion of the 400 rim wide amyloid filaments formed by full-length Ure2p leaves narrow filaments morphologically similar to those formed by the prion domain alone and composed of the prion domain (30~. Aggregated Ure2p from LURES] cells shows little reaction with This paper results from the Arthur M. Sackier Colloquium of the National Academy of Sciences, "Self-Perpetuating Structural States in Biology, Disease, and Genetics," held March 22-24, 2002, at the National Academy of Sciences in Washington, DC. Abbreviations: TSE, transmissible bovine encephalopathy; GST, glutathione S-transferase; GFP, green fluorescent protein; USA, ureidosuccinate; YPAD, yeast extract peptone adenine dextrose. Data deposition: The sequences reported in this paper have been deposited in the GenBank database (accession nos. AF525165-AF525199). *To whom reprint requests should be addressed. E-mail: 1 073/pnas. 162349599

OCR for page 8
antibody to the prion domain, but reacts well with anti-Ure2C (31~. The same is true of Ure2p filaments seen by electron microscopy specifically in LURES] cells (31~. This observation suggests that, in this structure, the prion domain is inside and the C-terminal domain is outside. The Ure2p prion domain was fused to the N terminus of several enzymes with small substrates (34), including glutatione S- transferase (GST), which is similar to the C-terminal domain of Ure2p (18, 35, 36~. Amyloid formed in each case, and the enzymatic activity of the fusion proteins were essentially the same in the amyloid form as in the soluble form, when suitable correction was made for diffusion effects (34~. These results suggested that amyloid formation does not inactivate Ure2p function by changing the conformation of the C-terminal domain, but rather by either sterically blocking interaction of Ure2p with Gln3p or by Ure2p being diffusion-limited in its filament form (34~. Several of the fusion proteins formed monofilaments with a helical form. The helical repeat length was consistent within a given filament, but, remarkably, varied dramatically from one filament to another, even though the filaments were composed of the same fusion protein (34~. This finding indicates that the geometry of Ure2p filament formation is determined by some stochastic process that occurs during filament initiation. The epidemic of bovine spongiform encephalopathy in the United Kingdom, followed by over 100 human TSE cases caused by consumption of infected bovine material has highlighted the im- portance of cross-species transmission of the mammalian TSEs. A similar phenomenon has been demonstrated in variants of tPSI+] in which the region of Sup35 of various yeasts corresponding to the prion domain of Sup35Sc was fused to the S. cerevisiae C-terminal domain of Sup35 (37-39~. These studies demonstrated that the N termini of the Sup35 proteins of Pichia methanolica and Candida albicans can act as prion domains. Moreover, the divergence of these prion domains correlated with a "species barrier," much like that long documented for the mammalian TSEs. We previously showed that overexpression of fragments of Ure2p or fusions of such fragments with green fluorescent protein (GFP) could efficiently cure the PUREE prion (32~. Here we have defined the portions of Ure2N and Ure2C required for this curing activity. As one approach to the functional significance of the Ure2N curing region, we examined homologs of Ure2p and found strong conser- vation of this part of the otherwise rapidly evolving N-terminal domain. Materials and Methods Yeast Strains and Media. Media were as described by Sherman (40~. The ureidosuccinate (USA) uptake phenotype of ura2 strains was tested on synthetic dextrose plates to which was added the required amino acids and bases (except uracil) and 100 ,ug/ml of USA. S. cerevisiae "wild-type" cultures were obtained from three sources. Some were locally purchased; these include cultures sold for making bread (SAF Perfect Rise yeast, Lesaffre, Bruxelles, Belgium; Fleischmann Active Dry yeast,; Peter McPhie's Sour Dough strain, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda) as well as cultures sold for home beer and wine making (Red Star Dry Wine Yeast, Premier cuvee; Wyeast catalog no. 1007,, German Ale; Wyeast catalog no. 2112xL, California Lager; White Labs catalog no. WLP002,, English Ale yeast; Boots home beer making genuine brewers yeast). Yeast cultures from Centraalbureau voor Schimmelcultures (CBS, in the Netherlands (CBS400, palm wine from Elaies guineensis, Ivory Coast; CBS405, bill wine from Osbeckia grandiflora, West Africa; CBS429, ferment- ing must of champagne grapes; CBS2087 flower of lychee, Tonkin, China; CBS2247, grape must, Cape Province, South Africa; CBS3093, alpechin, Spain; CBS4734, from juice of sugar cane; CBS5112, grape must, Spain; CBS5287, grapes, Russia; CBS6216, Edskes and Wickner tap water, Rotterdam, The Netherlands; CBS7957, cassava flour, Sao Paulo, Brazil). Clinical isolates of S. cerevisiae (41) were kindly provided by J. McCusker (Duke University Medical Center, Durham, NC). YJM145 is a segregant from YJM128 which was cultured from the lung of a man with immune deficiency syndrome. YJM413 is a segregant from clinical isolate YJM454. YJM280 is a segregant from YJM273, which was cultured from peritoneal fluid of a patient. YJM320 is a segregant from YJM309, which was cultured from the blood of a patient. YJM326 is a segregant from clinical isolate YJM310. YJM339 is a segregant from YJM311, which was cultured from the bile tube of a patient. Saccharomyces bayanus (YJM562) and Saccharomycesparadoxus (YJM498) were kindly provided by J. McCusker. Candida glabrata (37A; ref. 42), Candida kefi~r (telemorph is Klayveromyces ma~xia- nus) (B4425) (43), Candida maltosa (B4430) (44), C. albicans (Darlington strain) (45), and Candida lipolytica (telemorph is Yarrowia lipolytica) (B3163) (46) were kindly provided by K. J. Kwon-Chung (National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda). Ashbya gossypii (47) was purchased from American Type Culture Collection (catalog no. 8717~. Plasmid Constructions. PCR used Pt' Turbo polymerase (Strat- agene) unless otherwise stated. Construction of yeast expression plasmids. pH7 (2,u LEU2 PADH1) and pH317 (2,u LEU2 PGAT 1) have been described (32, 48~. pH199, a 2,u LEU2 plasmid containing GFP under control of the ADH1 pro- moter, has also been described (32~. To create pH722 (LEU2 CEN PURE2), first the NheI-BamHI bordered ADH1 promoter of pH124 (32~ was replaced by the similarly bordered GAL1 promoter from pH250 (48), creating pH316 (LEU2 CEN PGA[~- Then, a 413-bp URE2 promoter fragment bordered byNheI and BamHI sites was amplified by PCR from S. cerevisisue strain S288C using oligos HE194 (5'- AGAGCTAGCTTAGTAGAGCTGTGTAGAG-3') and HE19Sb (5'-TTGGGATCCAACTTAATTTGCAGCTTAAAAC-3') and cloned into the EcoRV site of pBC KS + creating pH497. Replacing the NheI-BamHI bordered GAL1 promoter of pH316 with the similarly bordered URE2 promoter from pH497 resulted in pH722. Likewise, replacing the NheI-BamHI bordered GAL1 promoter of pH317 with the URE2 promoter from pH497 resulted in pH723 (~LEU2 2,u PURE21. The HindIII and XbaI sites were removed from the TRP1 gene in the 2,u TR~1 vector pRS424 (49) by site-directed mutagenesis using oligos HE128 (5'-AAGAGAGCCCCGAAAGTTTA- CATTTTATGTTAGCTG-3') and HE129 (5'-GGCCGCA- GAATGTGCTCTTGATTCCGATGCTGACTTG-3'), respec- tively, resulting in plasmid pH342. The ADH1 promoter was amplified from pH7 by using oligos HE66 (5'-AGAGCTAGCAT- TACGCCAGCAACTTCT-3') and HE67 (5'-ACAAGATCTTA- ATGCAGCCGGTAGAG-3') and ligated into PvuII digested pH342 creating pH401 (~TRP1 2,u PADH1) The TRP1 and ADH1 promoters are facing each other in this construct. Truncations of the Ure2p C terminus fused to GFP. pH328 contains the C-terminal part of URE2 starting at Asp-66 (32~. Further N- terminal deletions were made by amplifying URE2-GFP fusions from pH326 (32~. PCR products were cloned into the EcoRV site of pBC KS+ (Stratagene), sequenced, and inserted as BamHI- X7zoI fragments into the BamHI~ oI window of pH7. Deletions in the C-terminal fragment of the URE2-GFP fusion proteins were created through amplification of URE2 fragments from pH13 (32), cloned into the EcoRV site of pBC KS+ and sequenced. The truncated fragments bordered by BamHI and NotI sites were fused to GFP through exchange with the BamHI-NotI fragment from pVTG4 (32~. Plasmids expressing truncations of the Ure2p N terminus fused to GFP. pVTG4 containing a part of URE2 terminating at Arg-65 has been described (32~. Further N-terminal deletions were made by ampli- PNAS I December 10, 2002 | vol. 99 | suppl. 4 | 16385

OCR for page 8
Table 1. Curing and Implementation by Ure2C-6FP fusion proteins Complementation Plasmid URE2 part* GFP signal Curing, USA-/Total of ure2A pH328 1-2, 66-35~GFP + 40/40 pH409 1, 86-35 - GFP + 40/40 pH410 1, 106-35 - GFP + 40/40 pH550 1, 111-35~GFP + 40/100 pH495 1, 116-350GFP +/ - 0/100 pH411 1, 126-35 - GFP 0/40 pH445 1-2, 66-293-GFP + 0/40 pH444 1-2, 66-313-GFP + 0/40 pH443 1-2, 66-333-GFP + 0/40 pH494 1 -2, 66-34~GFP 0/100 pH760 1-2, 66-347-GFP + 98/100 pH 549 1 -2, 66-349-G FP + 100/100 pH199 -GFP + *The portions of Ure2p are shown as residue numbers. After the Ure2p portion is the sequence GGR followed by GFP. tCuring was assayed in strain YHE64 (MA Tcx ura2 leu2 trpl [URE3]) as USA- transformants/total. USA complemen- tation was assayed in strain YHE887 (MATrx ura2 /eu2 ure2). fying URE2-GFP fusions from pVTG4. PCR products were cloned into the EcoRV site of pBC KS+, sequenced, and transferred as BamHI-X7zoI fragments into the BamHI~ oI window of pH7. C-terminal truncations were made by amplifying the ADH1 promoter and parts of URE2 from pVTG4. PCR products were cloned into the EcoRV site of pBC KS+ and sequenced. The truncated URE2 fragments bordered byBamHI end NotI sites were fused to GFP through exchange with the BamHI-NotI fragment from pVTG4. In pH767, S33 is encoded by AGC instead of AGT, and in pH548, T41 is encoded by ACT instead of ACA. The URE2Nl-45-SGR-GFP fragment from pH547 was transferred as a BamHI-X7zoI fragment into the BamHI-XhoI window of pH401 creating pH792. Cloning URE2 from Different S. cerevisiae Strains. Yeast strains were grown on yeast extract peptone adenine dextrose (YPAD) to single colonies. Colonies were resuspended in 50 ,ul H2O containing 3 mg/ml zymolyase and incubated at 37C for 30 min. One microliter of this suspension was used to amplify the URE2 gene with oligos HE252 (5'-CTGCAAATTAAGTTGTACACC-3') and HE253 (5'-TTCCTCCTTCTTCTTTCTTTC-3'). PCR products were cloned into EcoRV digested pBC KS+ and sequenced. Cloning URE2 Homologs from Different Fungi. All yeasts were grown in liquid YPAD, harvested, and genomic DNA was extracted as described (50~. A. gossypii was grown on solid YPAD, and genomic DNA was extracted as described (51~. Degenerate PCR primers were designed based on the alignment of S. cerevisiae URE2 and C. albicans URE2 (strain SC5314 of C. albicans; http://www- Two degenerate sense strand primers, HE207 (5'-CCIAAYGGITTYAARGTIG- CIATH-3'; Y = C + T.; R = A + G; H = A + C + T) and HE208 (5'-GGICAYGCICCIATGATHGGICAR-3'), and three degenerate antisense strand primers, HE209 (5'-RTAI- GCIGCIGCGTTYTCIGTRTC-3'), HE210 (5'-RTCIACIACRT- TRTTCCAIGGIAC-3'), and HE211 (5'-CATCATRTGYT- TIGTCCAYTTRTA-3'), were used to amplify URE2 homologs by using PCR supermix (GIBCO/BRL). PCR products were cloned into pCR2.1/TOPO (Invitrogen) and sequenced. Based on these sequences, nested organism-specific inverse primer sets were de- signed. Genomic DNA was digested with one of a number of restriction endonucleases and the generated fragments were self ligated. The 5' and 3' regions of the URE2 homologs were amplified by using PCR supermix and cloned into pCR2.1/TOPO. To ensure 16386 1 1 073/pnas. 162349599 that full-length URE2 ORFs were identified, PCR primers were designed that hybridized to the 5' and 3' untranslated regions. After amplification of URE2, the PCR products were cloned into EcoRV- digested pBC KS+ and sequenced. No PCR product could be obtained that contained the 5' untranslated region of the URE2 gene of S. paradoxus. A PCR product could be obtained when genomic DNA of S. paradoxus was used in a PCR reaction with the S. bayanus-specific 5' oligo. Finally, the URE2 homologs were amplified by PCR using oligos that created a BamHI site followed by the nucleotides CAA upstream of the start AUG and aX7loI site immediately downstream of the stop codon. C. Iipolytica was amplified by using a PCR primer that created a HindIII site immediately downstream of the stop codon of URE2 as it contains an internal XhoI. PCR products were cloned into the EcoRV site of pBC KS+ (Stratagene) and sequenced. The different URE2 ORFs were cloned as BamHI~ oI fragments into the different expression vectors. Only C. Iipolytica URE2 was doned as aBamHI- HindIII fragment into the different expression vectors. If URE2 was expressed under the control of the S. cerevisiae URE2 promoter, the ORFs were first cloned into expression vectors containing the GAL1 promoter. Subsequently, the NheI-BamHI bordered GAL1 promoter was replaced by the similarly bordered URE2 promoter. Results Interaction Domains of Ure2p Based on Curing. We previously showed that overexpression of parts of Ure2p or of their fusions with GFP led to efficient curing of the tURE3] prion (32~. Ure2C (residues 66-354) fused to GFP could both complement the nitrogen regu- lation function of Ure2p and cure. We now find that the N terminus of the curing region of Ure2C (fused to GFP) is between residues 111 and 116, whereas its C terminus is between residues 333 and 349 (Table 1~. The amounts of fusion protein expressed from the various constructs was checked by the level of green fluorescence (Table 1~. Comparable amounts were expressed from most con- structs, but some constructs showed decreased expression, making the N terminus of the region needed for curing ambiguous. The minimal portion of the fusion proteins for complementing a ure27\ mutation is residues 86-354. Although overexpression of the N-terminal domain of Ure2p induces tURE3] prion formation, this same domain, when overex- pressed in a tURE3] strain, cures cells of the prion (32~. Curing also takes place when the Ure2p N terminus fused to GFP is overex- pressed in a tURE3] strain (32~. By making N- and C-terminal deletions in the Ure2 domain of these GFP fusion proteins (Table Edskes ancl Wickner

OCR for page 8
Table 2. N-terminal domain interactions with Ure2p Plasmid URE2 part GFPsignal* Interference,$ Curing,t USA-/total USA+/106 pH 199 -G FP + cytopl. 15/718 13 pVTG4 M1, M2-R65-GFP + 439/440 68,000 pH545 M1, N3-R65-GFP + 200/200 93,000 pH486 M1, N0R65-GFP + 100/100 73,000 pH762 M1, N5-R65-GFP + 100/100 22,000 pH487 M1, G6-R65-GFP + 9/300 11,000 pH408 M1, N7-R65-GFP + 229/340 109,000 pH763 M1, V9-R65-GFP + 197/200 35,000 pH764 M1, N11-R65-GFP + 6/180 79,000 pH349 M1, S13-R65-GFP + 0/118 71 pH350 M1, R20R65-GFP + cytopl. 1/118 3 pH351 M1, S30R65-GFP + 0/118 8 pH352 M1, N45-R65-GFP + cytopl. 0/118 3 pH769 M1-S33, S63-R65-GFP + cytopl. 5/100 4 pH768 M1-135, S63-R65-GFP + cytopl. 4/100 1 pH767 M1-F37, S63-R65-GFP + mainly cytopl. 4/100 4,600 pH442 M1-F39, S63-R65-GFP + 0/240 130,000 pH484 M1-V43, S63-R65-GFP 0/200 66 pH548 M1-N44, S63-R65-GFP + 129/300 60,000 pH547 M1-N45, S63-R65-GFP + 101/200 57,000 pH546 M1-N46, S63-R65-GFP + 80/200 61,000 pH485 M1-N47, S63-R65-GFP + 295/300 39,000 pH766 M1-N49, S63-R65-GFP + 86/100 70,000 pH441 M1-N50, S63-R65-GFP + 139/140 63,000 pH765 M1-S53, S63-R65-GFP + 95/100 53,000 *The GFP signal of most fusion constructs transformed into the [URE3] strain was aggregated. Others showed an even cytoplasmic distribution ('cytopl.'). tCuring was tested as in Table 1. tInterFerence was measured as USA+ cells per 1 o6 cells. All USA+ clones tested became USA- on loss of the plasmid, indicating that this is not [URE3] induction, but simply interference with Ure2p action. 2), we more accurately defined this tURE3] curing region. We find that residues 5-47 are needed for this curing activity. Comparable levels of protein were expressed for nearly all of the constructs as judged by the level of GFP fluorescence. Unstable Inactivation of Ure2p by Overexpressed Ure2N-GFP. Over- expression of Ure2N-GFP from pVTG4 ( OCR for page 8
Table 3. Amino acid changes in natural isolates of S. cerevisiae Strain Changes >1278b; YJM145; YJM413; YJM280; YJM326; SAF; Fleischmann; Boots home; None McPhie sourdough; CBS2087 Lychee, China; CBS4734 Sugar cane; CBS7957 Cassava flour Brazil; German Ale YJ M320 CBS400 Palm wine-ivory Coast; CBS405 Bili wine, West Africa CBS3093 Alpechin, Spain; CBS5112 Grape must Spain CBS5287 Grapes Russia English Ale; California lager; CBS6216 tap water Roterdam A224 A264 L231 V245 N23S CBS429 grapes, France; Red Star Wine; CBS2247 Grape must, S. Africa N70Y V258 YJM339 N43b S10, E260, R344 N43b means insertion of an asparagine residue after amino acid 43. A224 means a change in codon 224 without changing the amino acid encoded. 4~. The N-terminal regions show substantial divergence, although they remain asparagine/glutamine rich (Fig. 1~. Interestingly, the N-terminal region identified by deletion analysis as needed for curing of tURE3] is conserved among S. cerevisiae, S bayanus, S. paradoxus, C. glabrata, C. kefyr, and A. gossypii. This region is missing from C. maltosa, C. albicans, and C. Iipolytica. As C. albicans is an asexual organism, it was possible that this domain is missing in the particular strain we examined. However, a C. stellatoidae strain we examined (synonymous with C. albicans), and two addi- tional C. albicans strains (present in the database) all had N- terminal domains identical to the first C. albicans strain, and lacked the conserved N-terminal region. The URE2 sequences of S. bayanus and S. paradoxus are nearly identical, but differ in the asparagine-rich domain between Ser-40 and Leu-81 of the S. cerevisiae sequence, indicating a relative plasticity of this region. Complementation of a S. cerevisiae ure2 Deletion by URE2 Homologs. The URE2 ORFs of S. cerevisiae, S. bayanus, S. paradoxus, C. glabrata, C. keJ5yr,A. gossypii, C. maltosa, C. albicans, and C. Iipolytica were placed under control of the S. cerev~siae URE2 promoter in pH722 (LEU2 CEN PURE21- Complementation was assayed as the Table 4. Conservation of URE2 C-terminal domains Identity with S. cerevisiae, % Species Amino acid DNA Complementation S. Paradoxus S. Bayanus C Glabrata C Kefyr-1 C Kefyr-2 K. Lactis A. gossypii C Maltosa C Albicans C Lipolytica 100 99 92 91 91 91 89 82 80 78 94 85 78 79 79 77 71 73 73 66 t _/+* + Comparison starts at Ser-100 of S. cerevisiae and equivalent positions in other organisms. The sequence from K. Iactis was obtained from the GenBank database (gi: 14009513). Complementation is based on expression of the whole sequence with the S. cerevisiae URE2 promoter on a CEN plasmid in YH E888. *Not improved if the URE2 homolog is on a multicopy plasmid. 16388 1 inability to grow on USA plates. C. Iipolytica URE2 did not complement, andA. gossypii URE2 complemented weakly. For both the complementation was not improved significantly when ex- pressed from the 2,u plasmid pH723 (also under control of the S. cerevisiae URE2 promoter). All of the other homologs comple- mented the ure2 deletion in strain YHE888 (MA Tc~ ura2 leu2::hisG trpl::hisG ure2::G418), preventing USA uptake with ammonia, while allowing it with proline as a nitrogen source. Induction of [URE3] by Overproduced URE2 Homologs. The URE2 homologs were placed under control of the GAL1 promoter and overexpressed in a strain with an intact chromosomal S. cerevisiae URE2 gene. Induction of tURE3] was assayed as appearance of USA+ colonies (Table 5~. Only S. paradoxus and, to a slight degree, S. bayanus were able to induce the appearance of tURE3] at higher than background rates. The lower than background rates for most of the other homologs probably reflects their masking the sponta- neous tURE3] events by complementing the functional deficit of S. cerevisiae Ure2p and not being themselves inactivated by the S. cerevisiae tURE3] (see below). Curing of [URE3] by Overexpression of Ure2p Homologs. Each of the Ure2p homologs was expressed from the GAL1 promoter on a LEU2 CEN plasmid in strain YHE64 (MA Ta ura2 leu2 trpl tURE3~. Transformants were confirmed to still have tURE3; as judged by the USA+ phenotype (20 USA+ of 20 tested in each case). This finding shows that homolog production is effi- ciently repressed on glucose medium, a critical point for this experiment. Transformants were grown to single colonies on YPAGal2%Rafl% to overexpress the Ure2p homolog, and colo- nies were then replicaplated to leucine dropout plates containing dextrose. Leu+ colonies were spotted on a grid on dextrose media lacking leucine, and replicaplated twice to allow growth and dilution of any remaining heterologous Ure2p. Patches were then replicaplated to USA plates to score retention or loss of tURE3~. There was no curing by any of the Saccharomyces Ure2 or by the nonfunctional C. Iipolytica Ure2p. However, each of the other Ure2s completely cured tURE33. That this is curing, and not masking of the USA+ phenotype, is shown by the fact that the glucose-repressed transformants are USA+, and the cells are again repressed by glucose after the expression of homolog. Can Overexpressed Ure2N'~45-GFP Inactivate Ure2 Homologs? Strain YHE888 (ure2) containing plasmids expressing URE2 homologs Eciskes and Wickner

OCR for page 8
S. cerevis~ae S. paradoxus bayanus glabrata kefyr-1 kefyr-2 lactis gossypii MQQEIRNSNTPNTGSe~Pe~~eSeeee~HL~ SIDYTSRA------------------------- lipolytica maltose albicans ~c---interference domain--->~ ~c----------curing domain------------~ 1 10 20 30 40 50 60 MMNNNGNQVSN~SNAL~Q9NIGNRNSNTTTDQSNINFEFSTOV---NNNNNNNSSS-----NNNNVQN ~ e ~ A ---~ S NNNNN A MGDSRaTGTI~~aS~ eSGQ-----~ K ~ Y ~ NGL---~eV D GNHNLVNTSEDee-- MQQDMHNG-----GT~ TI~ S~ L~ AID~NQQQLMEEV~Q~SMNAFNIQQQHQQQQE MQQDMHNG-----GTe~TI~~eS~ aSLe~ AID~NQQQLMEEVeQ~SMNAFNIQQQHQQQQE~ MQQDMQNG-----GP~~TI~ S~ N~L~ SID~NQQQLLEEA~QGSINAYNAQ---QQQQEH MMSTDQHIQ 70 80 90 X-ray structure -> 1> S. c~revisiae NNSGRNGSQNNONENNIKNT-----hEQHRQQQQA-----------------------~ ------FSDMSHVEY S. paradoxus ~ S ~ G~ D~----_~________ _________________________ S. bayanus S N T N S D -----I ~ .- ----------------------------------~. C. glabrata eKD.SINTNMMSRQVP.QH.HGSQL.Q.E.MNE.Q---------------------------------- NP --- C. kefyr-1 VQKQQEQQaQQLQQQQQQQQQQQQQQQaQQ~ QLQQQQQLQQHHHHQQRQQHPNNNVQAGTSQQQML~QGANSIDS C. kefyr-2 VQK--~ QQLQQQQQQQQQQQQQQQ~QQ ~ ~Q-QQQQQLQQHHHHQQRQQHANNNVQAGTSQQQML~QGANSIDS K. lactis LQ--QQAQ QQLHMQQLQQAQQQQAQQ AH. QVHQ----VQHQHVQQ------DHMPIGQSQQQAMYQGPNPIDS A. gossypii ------------------------------P ..PLDELSRGAAGGPAAGGGPEGSNMVGASSAAQVTA.GGP.V.DS C. lipolytica MSGAHTISHLSAGLRSVNIGDQQQNEANLNLLQQQLENEAT.QTQQ C. maltose MeMeDQRIPQeTGDeSNNSNSN-NNNNNNNNTHTISNLSAGLKSVSLTDQQQNEVNLNLLQQQLHRESSNQQQQ C. albicans MeDNS.NeN.SNeN.TNNeNNNQSVNVNVNNTNNNTQTISNLSAGLKSVSLTDQQQNEVNLNLLQQQLHQEASTQQQQ 100 llQ 120 130 140 150 160 170 6, cerevisiae SRIT~FFQEQPLEGYT~FSHRSAPNGFKVAIV~SELGFHYNTIFLDFN~GEHRAPEFVSVNPNARVPALIDHGMDNLS S. paradoxus Se bayanug C. glabrata C. kefyr-1 C. kefyr-2 K. lactis A. gossypii C. lipolytica C. maltose C. albicans e ~ ~ e ~ eNe e e e e ~ e e N ~M N~~M N~~M L Q AQ SD .~. e ~ eI~ ~ aELPF. e e ~ ~ ~ e ~He eQ~ ~ e ~ e eTI~ oFN..T. Q ~~N~ ~Ae ~ e ~ aI e ~NLPF.~. e ~ aN..Q. e e e ~ aTIe ~ ~ ~ e ~ ~ ~ e ~ eFNE~T ~ ~ ~ eQ~ ~ eNe eTe eFe e e e e e e e e e e e e e e eIe e ~ eNLpFe eFe e e ~ aN~eQ~T~ TI~~~ e e e ~ e eYNe ~T Fig. 1. Alignment of Ure2p homologs from yeasts and a filamentous fungus by using GCG pileup. The "." indicates identity, whereas "-" indicates a gap. S and T residues are red, and Q and N residues are green. The C-terminal (nitrogen regulation) domain begins at residue 100 in the S. cerevisiae sequence and continues to residue 354, though the figure only shows through residue 174. The "interference domain" is the portion of Ure2N which when overexpressed as a GFP fusion interferes with Ure2p activity. The "curing domain" is the portion that, fused to GFP, is needed for curing [URE3]. (LEU2 CEN PURE2URE2hm~g) was transformed with either pH401 (TRP1 2,u PAHD1) or pH792 (TRP1 2~ PAHDJURE2N1 45 GFP), and transformants were plated at serial dilutions on USA plates. Only the S. cerevisiae Ure2p was inactivated through over- expression of URE2Ni-45-GFP. Transformants containing the S. cerevisiae, C. glabrata, or C. kefyr URE2 were also plated quantitatively giving the same result as above. It is surprising that the nearly identical S. bayanus and S. paradoxus Ure2s were not inactivated. The fact that the source of Ure2p determined whether interference was observed indicates that Ure2Ni~4s was not interfering with the action of another component of the nitrogen control pathway. Ability of Ure2 Homologs to Propagate 1URE3]. URE2 homologs were expressed in strain YHE888 (ure2) under control of the S. cerevisiae URE2 promoter from a centromeric LEU2 plasmid. [URE3] was introduced into these strains by cytoduction from strain 4833-3B (~MATa ura2 argl karl-1 tURE3-1]), and the cytoductants were examined for the USA phenotype. Only the URE2 homologs from S. bayanus (11 USA+ of 11 cytoductants) and S. paradoxus Edskes and Wickner (6 USA+ of 11 cytoductants) were able to propagate [URE3]. These are the same two Ure2s that can induce S. cerevisiae tURE3] appearance when overexpressed. The Ure2s of C. kefyr (both genes), C. albicans, C. maltosa, and C. glabrata gave only USA- cytoductants. The Ashbya Ure2p could not be tested because of its incomplete complementation ability. Discussion Curing of [URE3]. Because propagation of tPSI+] (52) and tURE3] (53) require HsplO4, interference with its production can cure either prion. Guanidine at millimolar concentrations can also cure either tPSI+] (54) or [URE3] (12, 55) by a mechanism that appears to involve inactivation of Hsp-104 (56, 574. tURE3] is also cured by overexpression of parts of Ure2p, particularly when they are fused to GFP (32~. This curing by the "hair of the dog" method has a potentially broad application, and is known to be effective in curing tissue culture cells of PrP (58~. We proposed that the Ure2p fragments or fusion proteins join the growing filaments, but do not themselves provide a growing point, thus poisoning the linear amyloid crystal, but there are other possibilities. PNAS | December Jo, 2002 | vol. 99 | supp~. 4 | 16389

OCR for page 8
Table 5. Ability of URE2 homologs to induce or cure [URE3] in S. cerevisiae URE2 gene Plasmid Induction, USA+/106 cells Plasmid Curing, USA+/USA- Ve~or pH317 22 pH316 39/1 S. cerevisiae pH739 7,700 pH740 40/0 5. bayanus pH661 52 pH679 40/0 S. paradoxes pH660 6,300 pH678 40/0 C. glabrata pH659 <1 pH677 0/40 A. gossypii pH656 1 pH674 0/40 C. kefyr-1 pH713 2 pH711 0/40 C. kefyr-2 pH714 2 pH712 0/40 C. albicans pH563 6 pH672 0/40 C. maltose pH657 <0.1 pH675 0/40 C. Iipol~ica pH658 22 pH676 40/0 Strain YHE711 (MA T`x ura2 leu2::hisG) was transformed with 2,u plasmids carrying URE2 homologs under control of the GAL1 promoter. Individual transformants were grown to saturation in leucine dropout medium containing 2% galactose and 1% rafinose and plated in 10-fold dilutions onto USA plates to assay [URE3] induction. For curing, centromeric plasmids were transformed into YHE64. Transformants were confirmed to still carry [URE3], then grown to single colonies on YPAGal2%Raf2% to overexpress the Ure2p homolog. Leu+ colonies were grown as patches three times on dextrose, then tested for USA phenotype. Here, we defined the parts of the C-terminal and N-terminal domains of Ure2p necessary for their curing activities. The borders of the part of Ure2C needed for curing tURE3], are approximately residues 111 and 347. The domain needed for complementation is larger, extending from approximately residue 86 to residue 354. Interaction of Ure2p with Gln3p requires at least Ure2p residues 151-330 (22), and dimer formation has been demonstrated for Ure2p residues 90-354, but not for Ure2p residues 111-354 (33~. The C-terminal domain of Ure2p may cure tURE3] by forming heterodimers with the full-length Ure2p. This interaction might compete with its incorporation into the filaments. tURE3] prion stability is not affected by the nitrogen source (29), so it is unlikely that interactions with Gln3p or other factors involved in nitrogen regulation explain this curing phenomenon. Mkslp is necessary for tURE3] prion generation, not for propagation, indicating that possible interactions with this protein are not likely to be involved. By using the yeast two hybrid method, evidence for an interaction of Ure2p residues 1-96 with Ure2p residues 152-354 has been obtained (59~. However, our results show that a larger segment of Ure2C is needed for the curing, arguing against explaining the curing by this interaction of N terminus and C terminus competing for N terminus-N terminus interactions. We find that the part of Ure2N (as a fusion with GFP) needed for curing of tURE3] is N5 to N47, a relatively short region. In this case, the crystal poisoning mechanism, in which "impurities" pre- vent crystal growth, is particularly attractive. A slightly smaller region, amino acid residues N11 to N44, is necessary for interfering with Ure2p activity on overexpression. All of the constructs able to interfere with Ure2p appear to be aggregated as judged by the nonhomogeneous distribution of GFP fluorescence. It is possible that the overexpressed Ure2-GFP fusion protein forms aggregates that sequester the full-length Ure2p, but that these aggregates are not self propagating, or at least do not initiate a self-propagating aggregation of the full-length Ure2p. Negative complementation of Sup35p by a fragment of its prion domain has also been observed, but whether or not this is associated with aggregation is not yet known (60~. Whatever the mechanism of inhibition, the N11 to N44 region probably interacts with full-length Ure2p, though we do not yet have direct evidence for this interaction. This region corresponds quite closely with the part of the N-terminal domain that is conserved among a group of Ure2p homologs (Fig. 1~. The conservation of this region, despite wide divergence of sequence in the N-terminal part, suggests that this region is important for some function. In addition to the two-hybrid data (59), functional data suggests that Ure2N and Ure2C interact. Deletion of Ure2 residues 1-65 weak- 16390 1 1 073/pnas. 162349599 ens the ability of Ure2C to carry out its function in nitrogen regulation (29~. Likewise, deletions of all or parts of Ure2C dramatically increase the frequency with which Ure2p changes to the prion form (26), suggesting that the C-terminal domain stabi- lizes the N-terminal prion domain, perhaps by an interaction. Ure2 Homologs. In surveying clinical isolates, brewing strains, and baking strains of S. cerevisiae from a variety of sources, we find that the URE2 sequence is well conserved, and the few amino acid changes observed are in the N-terminal prion domain. Similar results were obtained by Jensen et al. (61) studying the Sup35 protein. Examination of URE2 genes from a series of yeasts and the fungus A. gossypii shows that the C-terminal part of Ure2p is highly conserved. Although Ure2p is homologous to the ~ group of GSTs (18, 62), that similarity is only about 30~o, whereas these proteins are 80-90% identical to each other in their C-terminal domains. For example, the "cap region" constitutes a loop with an c~ helix (36) of the S. cerevisiae Ure2p that is missing in most GSTs, but is present in all of the Ure2p homologs studied here as well as in that of Klayreromyces lactis (GenBank accession no. AAK;51642~. More- over, most of the yeast and fungal homologs fully complement the S. cerevisiae ure27\ mutant, indicating that the nitrogen regulation function is conserved. Unlike other ~ class GSTs, the S. cerevisiae Ure2p has Ala-122 and His-187 instead of the consensus Ser and Tyr, respectively. In the sequences obtained here, the Ala for Ser substitution is main- tained, but the C. Iipolitica, C. maltosa, and C. albicans Ure2 proteins contain the consensus Tyr-187, and the consensus Gly-136 is replaced with Asp in C. ke~r, K lactis, C. maltosa, and C. albicans and with Glu in C. Iipolitica. Thus, all of the Ure2p homologs diverge at critical residues from the GST consensus sequence. All of the Ure2 homologs studied here have an asparagine/ glutamine-rich N-terminal extension not found in the enzymatically active GSTs or in homologs from Schizosaccharomyces pombe or Neurospora crassa (ref. 63 and Interest- ingly, precisely those homologs with an N-terminal extension have the "cap region" insert in the C-terminal domain. Are they func- tionally related? The functional significance of the N-terminal extension of Ure2p remains a mystery. It is unlikely that prion formation helps cells regulate nitrogen catabolism, because it differs from the normal regulation mainly in lacking flexibility. Although Ure2C can regulate nitrogen catabolism without the prion domain, this regulation is less efficient than that carried out by the full-length Ure2p (26, 29~. This helper activity of the N terminus may be sufficient to explain its retention in evolution. A domain that is only present in yeasts closely related to S. Edskes ancl Wickner

OCR for page 8
cerevisiae and the filamentous fungusA. gossypii (also closely related to S. cerevisiae) is the region between S10 and 135. The conservation of this region, despite the wide sequence divergence of the remain- der of the N termini, suggests the presence of some functional constraint. There is no similarly conserved portion of the Sup35p prion domain (37-39~. The curing of tURE3] by homologs of Ure2p is striking in that all complementing Ure2s can cure except for the Ure2s of Saccha- romyces species, which can participate in the LURES] process. The results suggest that the C-terminal domain is doing the curing in these cases. However, it is not the complementationper se masking the tURE3] phenotype, because cells are assayed for tURE3] when the expression of the homolog is repressed on glucose. Species Barrier for [URE3]. Our efforts to transmit tURE3] from S. cerevisiae Ure2p to Ure2p of other fungi was only successful for the Ure2s from other Saccharomyces species. These were the most closely related in N-terminal sequence, and would thus be expected to have the lowest barrier to transmission. The fact that transmission of LURES] was not observed to the C. glabrata or C. keeper Ure2 1. Weissmann, C., Enari, M., Klohn, P.-C., Rossi, D. & Flechsig, E. (2002) Proc. NatL Acad. Sci. USA 99, Suppl. 4,16378-16383. 2. Dickinson, A. G., Meikle, V. M. H. & Fraser, H. (1968) J. Comp. Pathol. 78, 293-299. 3. Oesch, B., Westaway, D., Walchli, M., McKinley, M. P., Kent, S. B., Aebersold, R., Barry, R. A., Tempst, P., Templow, D. B., Hood, L. E., et al. (1985) Cell 40, 735-746. 4. Carlson, G. A., Kingsbury, D. T., Goodman, P. A., Coleman, S., Marshall, S. T., DeArmond, S., Westaway, D. & Prusiner, S. B. (1986) Cell 46, 503-511. 5. Hsiao, K, Baker, H. F., Crow, T. J., Poulter, M., Owen, F., Terwilliger, J. D., Westaway, D., Ott, J. & Prusiner, S. B. (1989) Nature (London) 338, 342-345. 6. Prusiner, S. B., Scott, M., Foster, D., Pan, K.-M., Groth, D., Mirenda, C., Torchia, M., Yang, S.-L., Serban, D., Carlson, G. A., et al. (1990) Cell 63, 673-686. 7. Bueler, H., Aguzzi, A., Sailer, A., Greiner, R.-A., Autenried, P., Aguet, M. & Weissmann, C. (1993) Cell 73,1339-1347. 8. Alper, T., Cramp, W. A., Haig, D. A. & Clarke, M. C. (1967) Nature (London) 214, 764-766. 39 9. Bolton, D. C., McKinley, M. P. & Prusiner, S. B. (1982) Science 218, 1309-1311. 10. Lacroute, F. (1971) J. Bacteriol. 106, 519-522. 40 11. Cox, B. S. (1965) Heredity 20, 505-521. 41. 12. Wickner, R. B. (1994) Science 264, 566-569. 13. Wickner, R. B., Edskes, H. K., Roberts, B. T., Pierce, M. & Baxa, U. (2002)Adv. Genet. 46, 485-525. 14. Bradley, M. E., Edskes, H. K., Hong, J. Y., Wickner, R. B. & Liebman, S. W. (2002) Proc. Natl. Acad. Sci. USA 99, Suppl. 4, 16392-16399. 15. Wickner, R. B., Taylor, K. L., Edskes, H. K., Maddelein, M.-L., Moriyama, H. & Roberts, B. T. (2001) Adv. Prot. Chem. 57, 313-334. 16. Wickner, R. B., Taylor, K. L., Edskes, H. K., Maddelein, M.-L., Moriyama, H. & Roberts, B. T. (1999) Microbiol. Mol. Biol. Revs. 63, 844-861. 17. Drillien, R. & Lacroute, F. (1972) J. Bacteriol. 109, 203-208. 18. Coschigano, P. W. & Magasanik, B. (1991) Mol. Cell. Biol. 11, 822-832. 19. Beck, T. & Hall, M. N. (1999) Nature (London) 402, 689-692. 20. Cardenas, M. E., Cutler, N. S., Lorenz, M. C., Di Como, C. J. & Heitman, J. (1999) Genes Dev. 13, 3271-3279. 21. Hardwick, J. S., Kuruvilla, F. G., Tong, J. K., Shamji, A. F. & Schreiber, S. L. (1999) Proc. Natl. Acad. Sci. USA 96, 14866-14870. 22. Kulkarni, A. A., Abul-Hamd, A. T., Rai, R., El Berry, H. & Cooper, T. G. (2001) J. Biol. Chem. 276, 32136-32144. 23. Cooper, T. G. (1982) in The Molecular Biology of the Yeast Saccharomyces: Metabolism and Gene Expression, eds. Strathern, J. N., Jones, E. W. & Broach, J. R. (Cold Spring Harbor Lab. Press, Plainview, NY), Vol. 2, pp. 39-99. 24. Rai, R., Genbauffe, F., Lea, H. Z. & Cooper, T. G. (1987) J. Bacteriol. 169, 3521-3524. 25. Magasanik, B. (1992) in The Molecular and Cellular Biology of the Yeast Saccharomyces, eds. Jones, E. W., Pringle, J. R. & Broach, J. R. (Cold Spring Harbor Lab. Press, Plainview, NY), Vol. 2, pp. 283-317. 26. Masison, D. C. & Wickner, R. B. (1995) Science 270, 93-95. 27. Maddelein, M.-L. & Wickner, R. B. (1999) Mol. Cell. Biol. 19, 4516-4524. 28. Kochneva-Pervukhova, N. V., Poznyakovski, A. I., Smirnov, V. N. & Ter-Avanesyan, M. D. (1998) Curr. Genet. 34,146-151. 29. Masison, D. C., Maddelein, M.-L. & Wickner, R. B. (1997) Proc. Natl. Acad. Sci. USA 94, 12503-12508. 30. Taylor, K. L., Cheng, N., Williams, R. W., Steven, A. C. & Wickner, R. B. (1999) Science 283, 1339-1343. 31. Speransky, V., Taylor, K. L., Edskes, H. K., Wickner, R. B. & Steven, A. (2001) J. Cell. Biol. 153, 1327-1335. Edskes and Wickner proteins from the S. cerevisiae Ure2p, despite all having the conserved sequence in the residue 10-40 region, indicates that this region is not sufficient to allow prion transmission. Similar results were obtained on testing the Ure2p homologs for ability to induce the de novo appearance of S. cerevisiae tURE3~. Only S. paradoxus, and to a slight extent S. bayanus, were able to induce tURE3] appearance. Others behaved like Ure2C (26) in showing an apparent decrease in frequency of tURE3], indicative of efficient complementation and inability to be affected by ~URE3~. C. Iipolytica did not induce, but does not complement ure21\ either, and showed a normal background frequency of tURE3~. Further work will be needed to determine whether the non- Saccharomyces Ure2ps can form prions on their own. It will also be important to determine whether the conserved S10 to I35 peptide participates in amyloid formation, and with what, if any, part of Ure2C it interacts. We thank Drs. June Kwon-Chung, John McCusker, and Peter McPhie for kindly supplying yeast strains. 32. Edskes, H. K., Gray, V. T. & Wickner, R. B. (1999) Proc. Natl. Acad. Sci. USA 96, 1498-1503. 33. Perrett, S., Freeman, S. J., Butler, P. J. G. & Fersht, A. R. (1999) J. Mol. Biol. 290, 331-345. 34. Baxa, U., Speransky, V., Steven, A. C. & Wickner, R. B. (2002) Proc. Natl. Acad. Sci. USA 99, 5253-5260. 35. Umland, T. C., Taylor, K. L., Rhee, S., Wickner, R. B. & Davies, D. R. (2001) Proc. Natl. Acad. Sci. USA 98,1459-1464. 36. Bousset, L., Beirhali, H., Janin, J., Melki, R. & Morera, S. (2001) Structure (London) 9, 39-46. 37. Chernoff, Y. O., Galkin, A. P., Lewitin, E., Chernova, T. A., Newnam, G. P. & Belenkly, S. M. (2000) Mol. Microbiol. 35, 865-876. 38. Kushnirov, V. V., Kochneva-Pervukhova, N. V., Cechenova, M. B., Frolova, N. S. & Ter-Avanesyan, M. D. (2000) EMBO J. 19, 324-331. Santoso, A., Chien, P., Osherovich, L. Z. & Weissman, J. S. (2000) Cell 100, 277-288. Sherman, F. (1991) Methods Enzymol. 194, 3-21. McCusker, J. H., Clemons, K. V., Stevens, D. A. & Davis, R. W. (1994) Genetics 136, 1261-1269. 42. Miyazaki, H., Miyazaki, Y., Gerber, A., Parkinson, T., Hitchcock, C., Falconer, D. J., Ward, D. J., Marsden, K. & Bennett, J. E. (1998) Antimicrob. Agents Chemother. 42, 1695-1701. 43. Collins, M. S. & Pappagianis, D. (1974) Sabouraudia 12, 329-340. 44. Bassel, J., Phaff, H. J., Mortimer, R. K. & Miranda, M. (1978) Intl. J. Syst. Bacteriol. 28, 427-432. 45. Kakeya, H., Miyazaki, Y., Miyazaki, H., Nyswaner, K., Grimberg, B. & Bennett, J. E. (2000) Antimicrob. Agents Chemother. 44, 2985-2990. 46. Barth, G. & Gaillardin, C. (1997) FEMS Microbiol. Rev. 19, 219-237. 47. Ashby, S. F. & Nowell, N. (1926) Ann. Bot. 40, 69-83. 48. Edskes, H. K. & Wickner, R. B. (2000) Proc. Natl. Acad. Sci. USA 97, 6625-6629. 49. Christianson, T. W., Sikorski, R. S., Dante, M., Shero, J. H. & Hieter, P. (1992) Gene 110, 119-122. 50. Pitkin, J. W., Panaccione, D. G. & Walton, J. D. (1996) Microbiology 142, 1557-1565. 51. Timberlake, W. E. (1980) Dev. Biol. 78, 497-510. 52. Chernoff, Y. O., Lindquist, S. L., Ono, B.-I., Inge-Vechtomov, S. G. & Liebman, S. W. (1995) Science 268, 880-884. 53. Moriyama, H., Edskes, H. K & Wickner, R. B. (2000) Mol. Cell. Biol. 20, 8916-8922. 54. Tuite, M. F., Mundy, C. R. & Cox, B. S. (1981) Genetics 98, 691-711. 55. Aigle, M. (1979) Ph.D. thesis (L'Universite Louis Pasteur de Strasbourg, Strasbourg, France), pp. 95. Jung, G. & Masison, D. C. (2001) Curr. Microbiol. 43, 7-10. . . Ferreira, P. C., Ness, F., Edwards, S. R., Cox, B. S. & Tuite, M. F. (2001) Mol. Microbiol. 40, 1357-1369. 58. Chabry, J., Caughey, B. & Chesebro, B. (1998) J. Biol. Chem. 273, 13203-13207. 59. Fernandez-Bellot, E., Guillemet, E., Baudin-Baillieu, A., Gaumer, S., Komar, A. A. & Cullin, C. (1999) Biochem. J. 338, 403-407. 60. Derkatch, I. L., Chernoff, Y. O., Kushnirov, V. V., Inge-Vechtomov, S. G. & Liebman, S. W. (1996) Genetics 144,1375-1386. 61. Jensen, M. A., True, H. L., Chernoff, Y. O. & Lindquist, S. (2001) Genetics 159, 527-535. 62. Rossjohn, J., Board, P. G., Parker, M. W. & Wilce, M. C. (1996) Protein Eng. 9, 327-332. 63. Wood, V., Gwilliam, R., Rajandream, M.-A., Lyne, M., Lyne, R., Stewart, A., Sgouros, J., Peat, N., Hayles, J., Baker, S., et al. (2002) Nature (London) 415, 871-880. 56. 57. PNAS | December 10, 2002 1 vol. 99 | suppl. 4 | 16391